The generation and expansion of functional T cells in vitro can lead to a broad range of clinical applications. One such use is for the treatment of patients with advanced cancer. Adoptive T cell transfer (ACT) of highly enriched tumor antigen-specific T cells has been shown to cause durable regression of metastatic cancer in some patients. However, during expansion, these cells may become exhausted or senescent, limiting their effector function and persistence in vivo. Induced pluripotent stem cell (iPSC) technology may overcome these obstacles by leading to in vitro generation of large numbers of less differentiated tumor antigen-specific T cells. Human iPSC (hiPSC) have the capacity to differentiate into any type of somatic cell, including lymphocytes, which retain the original T cell receptor (TCR) genomic rearrangement when a T cell is used as a starting cell. Therefore, reprogramming of human tumor antigen-specific T cells to hiPSC followed by redifferentiation to T cell lineage has the potential to produce rejuvenated tumor antigen-specific T cells. Described here is a method for generating tumor antigen-specific CD8αβ + single positive (SP) T cells from hiPSC using OP9/DLL1 co-culture system. This method is a powerful tool for in vitro T cell lineage generation and will facilitate the development of in vitro derived T cells for use in regenerative medicine and cell-based therapies.
Introduction
In addition to physiological advantages, T cells have many potential therapeutic applications. The generation and expansion of T cells in vitro can be used for disease modeling and therapeutic validation as well as a source of treatment for hereditary and acquired immunodeficiency states (i.e., viral immunodeficiencies and lymphodepletion secondary to chemotherapy or transplantation) and for the eradication of cancer. This latter quality has led to the development of adoptive T cell transfer (ACT) for the treatment of patients with advanced cancer 1 .
ACT consists of resecting a patient's tumor, extracting tumor-infiltrating lymphocytes (TILs), expanding TILs ex vivo, then reinfusing the expanded cells into the patient 2 . It has been shown to be an effective treatment modality for some patients with metastatic cancer. Unfortunately, not all patients respond to this therapy. Previous reports have shown that the differentiation state of transferred cells 3, 4, 5, 6, 7, 8, 9 , use of large numbers of highly enriched cancer antigen-specific T cells 10 , and persistence of T cells after transfer 11, 12 are all correlated with more durable responses 13, 14 . Therefore, when ACT fails to elicit an anti-tumor response, it may in part be due to a low yield of cancer antigen-specific T cells, inefficient ex vivo expansion leading to the exhaustion and loss of reactive clones, or lack of persistence after transfer 4 . It has been postulated that these obstacles may be overcome by the generation of large numbers of less differentiated cancer antigen-specific T cells in vitro 15, 16 . Hematopoietic stem/progenitor cells (HSPCs) are a conventional source for in vitro T cell generation, although this method is limited by the small number of cells able to be recovered from a single donor 1 . Embryonic stem cells (ESCs) have also been shown to produce T cells but with low yield 17 , making it inefficient for clinical applications. Furthermore, since T lineage cells experience stochastic genetic recombination of their T cell receptors (TCRs) in early developmental stages, it is not possible to use HSPCs or ESCs to generate a pure population of antigen-specific T cells without further genomic modifications like TCR gene transduction.
One approach to overcome these caveats is to reprogram TILs to human induced pluripotent stem cells (hiPSCs), which may provide a limitless source for in vitro T cell generation. It has been shown that cancer antigen-specific TILs can be reprogrammed into hiPSCs and re-differentiated to T cell lineage, which retains the same T cell receptor (TCR) gene rearrangement as the original T cell which should appear checkered. Detach cut colonies by gentle mechanical flushing using a 200 μL pipette. NOTE: Detachment of cut colonies by mechanical flushing must be done immediately after cutting colonies with the roller, because after 3 min the cut colonies will start to reattach to the dish, and it will become difficult to detach colonies of homogeneous size by flushing. 5. Transfer 350 -600 clumps of cut colonies onto a new 10 cm dish of MEF (plated 8 -36 h prior to hiPSC passaging) with 10 mL of fresh hiPSC media supplemented with 10 μM ROCK inhibitor. Incubate at 37 °C. NOTE: 600 clumps represents approximately 1.0 x 10 6 MART-1 iPSC and will yield 0.5-1.0 x 10 6 DP cells on day 35. However, expected numbers will vary depending on the potency of the starting cell line and culture conditions. 6. The following day, aspirate spent media and add 10 mL of fresh hiPSC media. Change hiPSC media every 1-2 days depending on hiPSC growth rate.
Preparation of OP9/DLL1 Cells for Co-culture with hiPSCs
1. Culture OP9/DLL1 cells in OP9 media [α-minimum essential medium (α-MEM) + 20% fetal bovine serum (FBS) + 1x penicillin-streptomycin] at 37 °C. When OP9/DLL1 cells reach confluency, aspirate media and wash once with 5 mL of 1x magnesium, calcium, and phenol red-free phosphate buffered saline (PBS). 2. Aspirate PBS and add 2 mL of 0.05% Trypsin-EDTA. Incubate for 5 min at 37 °C. Then, add 4 mL of OP9 media and mechanically dissociate the cell layer by pipetting to make a single-cell suspension. 3. Transfer the cell suspension into a 50 mL conical tube through a 100 μm cell strainer to avoid cell clumps. Centrifuge at 300 x g for 5 min at 4°C
. Aspirate the supernatant and resuspend in 12 mL of OP9 media. 4. Add 8 mL of OP9 media to each of six new 10 cm cell culture Petri dishes. Plate 2 mL of OP9/DLL1 cell suspension from step 2.3 onto each new 10 cm dish. Rock the dish side-to-side then front-to-back to ensure even distribution of OP9/DLL1 over the dish. 5. Incubate at 37 °C. Repeat passage every 2 -3 days when cells reach confluency.
NOTE: It is important to make enough frozen stock of OP9/DLL1 cells and thaw a new stock every 4-6 weeks. 2. After 4 days, add 10 mL of OP9 media to each 10 cm dish of OP9/DLL1 on gelatin, for a total of 20 mL of media per dish. 3. After 7 -8 days, begin the hiPSC co-culture on OP9/DLL1 confluent dishes (differentiation day 0). 1. Aspirate spent media from confluent 10 cm dish of hiPSCs on MEF. Add 10 mL of OP9 media. Cut and detach hiPSC colonies using a disposable cell passaging tool as done in steps 1.2.3 and 1.2.4. 2. Transfer 350 -600 clumps of cut colonies onto a 10 cm pre-gelatinized OP9/DLL1 dish (step 3.1) with 10 mL of fresh OP9 media using a 200 μL pipette. Rock the culture dish side-to-side then front-to-back to ensure even distribution of colonies. NOTE: Alternatively, pre-formed hiPSC embryoid bodies (EBs) or small clump suspension may be used. However, the use of a disposable cell passaging tool or EB formation system is preferred to produce hiPSC clumps of uniform size.
In Vitro Differentiation of hiPSCs into CD8αβ
4. On day 1, aspirate spent media and replace with 20 mL of fresh OP9 media. hiPSC clumps co-cultured on OP9/DLL1 for 1 day will appear as small round monolayer colonies (Figure 1) . 5. On day 5, aspirate 10 mL of spent media and add 10 mL of fresh OP9 media. hiPSC colonies will begin to differentiate into primitive mesoderm, which is characterized by a multilayered dark center. 6. On day 9, aspirate 10 mL of spent media and add 10 mL of fresh OP9 media. At this point, multilayered center structures will evolve into dome-like shapes, and a peripheral network-like area will start to become evident. 7. On day 13, harvest hematopoietic progenitor cells (HPCs) (Figure 1 ). hiPSC-derived structures on day 13 are characterized by a dark central organoid surrounded by a network of dome-like areas, representative of hematopoietic zones (HZs) previously reported to enclose human embryonic stem cell-derived hematopoietic progenitors 21 .
NOTE:
The presence of the dome-like structures indicates a successful process even in the absence of dark centers. The inability to produce HPCs may be due to poor quality of OP9/DLL1, quality of FBS lot, confluency of iPSC clumps seeded onto OP9/DLL1 (350-600 clumps is optimal), and/or variations in potency of iPSC lines to produce hematopoietic precursors.
1. Aspirate spent media and wash 1x with 5 mL of 1x phenol red-free Hanks' balanced salt solution modified with calcium and magnesium (HBSS). 2. Aspirate HBSS and add 250 μL of 5000 Units/mL collagenase IV in 10 mL of HBSS. Incubate at 37 °C for 45 min. Aspirate HBSS with collagenase IV and wash once with 5 mL of PBS. 3. Aspirate PBS and add 5 mL of 0.25% Trypsin-EDTA. Incubate at 37 °C for 20 min. Then, add 4 mL of OP9 media and dissociate the cell layer by pipetting to make a single-cell suspension. 4. Transfer the cell suspension into a 50 mL conical tube through a 100 μm cell strainer. Centrifuge at 300 x g for 5 min at 4 °C. Aspirate the supernatant and resuspend in 10 mL of OP9 media. 5. Plate cell suspension onto a new gelatinized 10 cm cell-culture Petri dish (see steps 3.1.1 and 3.1.2). Incubate at 37 °C for 45 min.
Then, collect non-adherent cells by gentle pipetting. 6. Transfer collected cell suspension into a 50 mL conical tube through a 100 μm cell strainer. Centrifuge at 300 x g for 5 min at 4 °C.
Aspirate Add 100 IU human interleukin 2 (hIL-2), 5 ng/mL hIL-7, 500 ng/mL anti-human CD3 antibody, and 2 μg/mL anti-human CD28 antibody, then culture at 37 °C. 4. On day 4 -7 after stimulation, collect cells for molecular analysis (Figure 3) or co-culture with peptide-pulsed antigen presenting cells (APCs).
Measuring Antigen Specificity of hiPSC Derived CD8αβ + SP T Cells NOTE:
The type of APCs to be used for this experiement is dependent on the MHC restriction of hiPSC-derived T cells. Here, T2 cell line is used, which is a hybrid of T and B lymphoblastoid cell lines. T2 cells express HLA-A*02:01 23 , which is recognized by JKF6 cells from which MART1-iPSC was derived 18 . This T2 cell line can be expanded in RPMI 1640 + 20% FBS + 1x penicillin-streptomycin and is passaged when cells reach a density of 5 x 10 5 cells/mL. 
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Representative Results
After 13 days hiPSCs co-culturing with OP9/DLL1, CD34 + CD43 + hematopoietic progenitor cells appeared (Figure 1) . After an additional 22 days of culture on non-gelatinized OP9/DLL1 in the presence of hSCF, hFLT3L, and hIL-7, hematopoietic progenitors differentiated into CD3 + CD7 + CD4 + CD8 + double-positive (DP) T lineage cells, the majority of which expressed TCR specific to the MART-1 epitope (tetramer) (Figure 2) .
It has previously been shown that CD8 + SP T cells can be induced from CD4 + CD8 + DP T cells by TCR signaling via agonist peptide or antibodydriven TCR stimulation 24, 25 . Therefore, on day 35 of culture, hiPSC-derived CD4 + CD8 + DP T cells were stimulated with anti-human CD3 and anti-human CD28 antibodies in the presence of hIL-7 and hIL-2. Four days after stimulation, the number of CD3 + CD8αβ + SP cells increased dramatically and remained specific for the MART-1 epitope, confirming the preservation of their inherited antigen-specificity (Figure 3) .
To 
Discussion
The co-culture of OP9 murine stromal cells is a well-established system for in vitro generation of lymphocytes (i.e., NK, B, and T cells) from HSPCs and pluripotent stem cells. Notch signaling is required to induce T lineage commitment and can be accomplished by the ectopic expression of Notch ligand DLL1 or DLL4, which have comparable efficacy for T cell generation 1 1 . Additionally, a T cell product with a single TCR recombination cannot be generated from these open repertoire sources. By using regenerative medicine techniques, namely induced pluripotent stem cell (iPSC) technology, it may be possible to produce massive numbers of antigen-specific T cells for use in cell-based therapeutics 15 .
hiPSCs are similar to pluripotent ESCs in their capacity for self-renewal, limitless expansion, and potential to differentiate to any type of somatic cell in the body; however, they lack the ethical concerns surrounding the use of products of embryonic origin for clinical applications. Moreover, hiPSCs can be produced from any somatic cell, allowing the development of cell products for personalized medicine. In previous reports, hiPSCs have been produced from human T cells using whole peripheral mononuclear cells, CD3 + cells, or isolated cytotoxic T lymphocytes (CTLs) as a source 18, 19, 22, 26 . When hiPSCs are generated from a T cell source (T-iPSCs), the original TCR gene rearrangement is inherited. Therefore, patient T-iPSC derived T cells may provide a model for personalized ACT treatment by targeting a patient's distinct cancer antigens.
The differentiation of human pluripotent stem cells into T lineage cells is divided into two steps: the generation of hematopoietic progenitor cells (HPCs) 27 and their further differentiation into T lineage cells 21 . Both steps can be accomplished using the OP9/DLL1 co-culture system. Importantly, the quality of OP9/DLL1 feeder cells is critical to the success of T cell differentiation. Since OP9/DLL1 cells are not an immortalized homogenous cell line, the quality of the FBS and culture conditions are critical to maintaining their expansion without losing the ability to support hiPSC differentiation. Therefore, it is recommended to pre-evaluate the lot of FBS and passage consistently when cell-to-cell cytoplasmic contact begins to occur, in order to prevent cell differentiation and senescence. One point to take into consideration is that cell-to-cell contact can appear indistinguishable from the background depending on the phase contrast and magnification of the microscope. In our experience, most OP9/DLL1 dishes will appear to be 80% confluent when ready to passage.
It has been shown that the redifferentiated T lineage cells generated from T-iPSCs by OP9/DLL1 co-culture can produce CD8 + SP T cells upon stimulation 18, 19 . However, regenerated CD8 + SP T cells acquire the innate-like CD8αα homodimer 22, 28 , which is an ineffective co-receptor for TCR signaling 29 . Additionally, these regenerated CD8 + SP T cells have shown strong TCR-independent cytotoxicity, making these cells unfavorable for clinical use 30 . This protocol describes a recent method involving stimulation of purified CD4 + CD8 + DP cells to generate CD8αβ + SP T cells with a more conventional phenotype and improved antigen-specific cytotoxicity 22 . Although the loss of antigen specificity due to secondary TCRα allelic rearrangement occurs in the DP stage after prolonged long-term culture, this can be overcome by genome editing in T-iPSCs 31 . In our experience, hiPSC-derived DP cells start to appear on day 30 -35 of culture, and these newly generated DP cells have not yet undergone secondary TCRα rearrangement. Therefore, most DP cells on day 35 retain antigen specificity and can be used to generate antigenspecific CD8αβ + SP T cells.
Prior to human anti-CD3 and anti-CD28 stimulation on day 35, CD4 -CD8 -DN cells must be removed from the culture, as these have been demonstrated to cause direct killing of CD4 + CD8 + DP cells after stimulation 22 . Using CD4 magnetic bead enrichment (step 3.10) will enrich for both DP and CD4 + CD8 intermediate single positive (ISP) cells 1 , which we have been shown to have no negative effects 22 . Alternatively, fluorescence-activated cell sorting by flow cytometry can be performed to isolate DP cells. However, magnetic bead separation is preferred as it avoids the mechanical stress induced by flow cytometry.
The generation of CD8αβ + SP T cells from human pluripotent stem cells without activation-mediated agonist selection has subsequently been demonstrated by the use of 3D murine stromal cell culture 32 . However, physiological positive selection is dependent on the interaction of TCR with self-peptide-MHC complexes, which are uniquely processed and presented by thymic cortical epithelial cells 33 . Furthermore, TCR affinity for selection peptides has been shown to determine the subsequent functional capabilities of mature CD8αβ + SP T cells 34 . Currently, there is no evidence to suggest that a Notch stromal cell-based co-culture system can provide the defined selection peptide and MHC complex required for physiological positive selection.
It has been previously reported in a murine model that T lineage cells generated from tumor antigen-specific T cell-derived hiPSCs using OP9/ DLL1 alone fail to experience conventional maturation. However, iPSC-derived immature T cells generated by the OP9/DLL1 system can mature into naïve-like T cells by further physiological thymic education in a 3D culture system 28, 35 . Therefore, the protocol presented here to produce iPSC-derived immature T cells generated by the OP9/DLL1 system is vital for further attempts to generate real human tumor antigen-specific post-thymic T cells capable of long-term persistence in vivo with efficiency to treat established vascularized tumors.
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